Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference
November 09, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
November 04, 2021 07:00 ET
|
Passage Bio
On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01 for the treatment of infantile GM1 in 4Q21Activated multiple clinical sites...
Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
October 28, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Participate in Upcoming October Conferences
September 27, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS)...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2021 16:01 ET
|
Passage Bio
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors
September 07, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference
September 02, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 27, 2021 16:01 ET
|
Passage Bio
PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
August 05, 2021 07:00 ET
|
Passage Bio
Expanded strategic collaboration with University of Pennsylvania’s Gene Therapy Program to advance genetic medicines for large CNS diseases, initially focused on Alzheimer’s Disease and Temporal Lobe...
Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.
August 04, 2021 21:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...